Using the HER2-positive GC cell lines NCI-N87 and SNU-216, along with CDX mouse models, we demonstrated that the combination of a YAP inhibitor and trastuzumab leads to growth inhibition and cycle arrest in HER2-positive GC cells, enhancing anti-tumor efficacy in mice. Here, YAP1 is linked to gastric cancer.